View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Unde...

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on August 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 75,850 shares of its common stock and granted an aggregate of 53,400 restricted stock unit (“RSU”) awards to 27 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement ...

 PRESS RELEASE

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Result...

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update       Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date       Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year       $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2...

 PRESS RELEASE

Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Prefer...

Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...

 PRESS RELEASE

Texas Capital Bancshares, Inc. Announces Second Quarter 2025 Results

Texas Capital Bancshares, Inc. Announces Second Quarter 2025 Results Second quarter 2025 net income of $77.3 million and net income available to common stockholders of $73.0 million, up 86% and 95%, respectively, year-over-year Second quarter 2025 EPS of $1.58 per diluted share and adjusted EPS(1) of $1.63 per diluted share, up 98% and 104%, respectively, year-over-year Strong balance sheet growth with total loans increasing 7% quarter-over-quarter and 10% year-over-year Book Value and Tangible Book Value(2) per share both increasing 13% year-over-year, reaching record levels DA...

 PRESS RELEASE

Crinetics to Present New Long-Term Data Demonstrating Durable Control ...

Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025 Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies Additional PALSONIFY presentations demonstrate reductions in patient-reported symptom burden, including both symptom severity and rates of symptom flares SAN DIEGO, July 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced new data from its clinical development program e...

 PRESS RELEASE

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Resu...

Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803    Webcast: Participants can use the dial-in number...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: July 10, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under ...

Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Pla...

 PRESS RELEASE

Texas Capital Bancshares, Inc. Announces Date for Q2 2025 Operating Re...

Texas Capital Bancshares, Inc. Announces Date for Q2 2025 Operating Results DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the second quarter of 2025 before market on Thursday, July 17, 2025. Executive management will host a conference call and webcast to discuss second quarter 2025 operating results on Thursday, July 17, 2025, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting  and will receive a unique PIN number to b...

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: July 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Crinetics to Showcase the Next Generation of Endocrinology Innovation ...

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching treatments and those not previously pharmacologically treated Atumelnant Phase 2 trial results in congenital adrenal hyperplasia (CAH) to be featured in oral presentation Data from early-stage development program in Graves’ hyperthyroidism and orbito...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: June 27, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MarketLine Department
  • MarketLine Department

Southside Bancshares Inc - Company Profile and SWOT Analysis

Summary Southside Bancshares Inc - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Southside Bancshares Inc (SBSI) is a bank holding company operating through its subsidiary, Southside Bank, which provides a range of financial services. The company's main activities include o...

 PRESS RELEASE

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025

Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025 SAN DIEGO, June 16, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that it will host an in-person and virtual R&D Day in New York on Thursday, June 26, 2025, from 9:00 AM to 12:00 PM ET. The event will provide an update including data on Crinetics' early-stage pipeline assets, next steps, and portfolio strategy to drive long-term value. Key topics will include: NETs and beyond – NDC platform with CRN09682Graves’ disease and thyroid eye disease (TED) - TSH antagonistAutosomal polycystic k...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 14, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under ...

Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit (“RSU”) awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Pla...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: June 7, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch